Lead Product(s) : Mosnodenvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
J&J Drops Phase 2 Dengue Candidate as Part of Ongoing Move Away from Vaccines
Details : JNJ-1802 (mosnodenvir) is an antiviral small molecule drug candidate, which is currently being evaluated for the treatment of patients with dengue infection.
Product Name : JNJ-1802
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2024
Lead Product(s) : Mosnodenvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mosnodenvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-1802 is effective against all four of the dengue serotypes in mouse models and provides strong protection against two tested serotypes in non-human primates. prevents the interaction between NS3 and NS4B, thereby stopping the ability of the virus to ...
Product Name : JNJ-1802
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : Mosnodenvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable